Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Sunrun Inc (RUN) vs Viatris Inc (VTRS) Price & Performance

Sunrun IncTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

Sunrun Inc vs Viatris Inc — how do they compare? Sunrun Inc trades at $11.5 (market cap $2.73B), while Viatris Inc trades at $17.58 (market cap $19.79B). The key difference: Viatris Inc is far larger — about 7.2× Sunrun Inc's market cap, and Viatris Inc pays a 2.83% dividend while Sunrun Inc pays none. Which is the better fit depends on your goals.

RUNVTRS
Market Cap
$2.73B$19.79B
Sector
TechnologyHealth
52-Week High
$21.41$17.39
52-Week Low
$9.07$8.74
Enterprise Value
$16.92B$32.00B
Dividend Yield
2.83%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Sunrun Inc

No Aura AI signal available yet.

Viatris Inc

Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.

The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.

Returns comparison

Trailing returns across standard periods

About Sunrun Inc

Sunrun Inc. is one of the largest residential solar, battery storage, and energy services companies in the United States. The company provides solar panel installations, battery backup systems, and energy management solutions to homeowners. Sunrun primarily uses a solar-as-a-service model, offering customers solar leases and power purchase agreements (PPAs), which allow homeowners to adopt solar energy with little to no upfront cost. The company's mission is to create a planet run by the sun.

Read more on RUN

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS